Omnicell (NASDAQ:OMCL) Updates FY 2026 Earnings Guidance

Key Points

• FY 2026 guidance: Omnicell raised its EPS outlook to 1.800–2.000 (consensus 1.600) and revenue guidance to $1.2B–$1.3B, and also updated Q2 2026 guidance (reported as 0.400–48.000 EPS).
• Market snapshot: Shares opened at $37.63 (trading up ~0.7%), market cap is about $1.71B, and the stock carries an elevated trailing P/E of roughly 941.
• Analyst view: Consensus is a "Moderate Buy" with a $59 average price target, based on six Buy, one Hold and one Sell ratings.

Omnicell (NASDAQ:OMCL - Get Free Report) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 1.800-2.000 for the period, compared to the consensus earnings per share estimate of 1.600. The company issued revenue guidance of $1.2 billion-$1.3 billion, compared to the consensus revenue estimate of $1.2 billion. Omnicell also updated its Q2 2026 guidance to 0.400-48.000 EPS.

Omnicell Trading Up 0.7%

Shares of OMCL opened at $37.63 on Tuesday. Omnicell has a 52-week low of $22.66 and a 52-week high of $55.00. The business's fifty day moving average is $36.86 and its 200-day moving average is $39.29. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.22 and a current ratio of 1.43. The firm has a market cap of $1.71 billion, a price-to-earnings ratio of 940.99, a PEG ratio of 1.34 and a beta of 0.85.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its quarterly earnings data on Tuesday, April 28th. The company reported $0.55 earnings per share for the quarter, topping analysts' consensus estimates of $0.33 by $0.22. The business had revenue of $309.88 million for the quarter, compared to analyst estimates of $304.01 million. Omnicell had a return on equity of 3.00% and a net margin of 0.17%.Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. Equities analysts anticipate that Omnicell will post 0.92 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on OMCL shares. Piper Sandler restated an "overweight" rating and set a $49.00 price objective (down from $63.00) on shares of Omnicell in a research report on Friday, February 6th. Weiss Ratings lowered Omnicell from a "hold (c-)" rating to a "sell (d)" rating in a research report on Monday, March 2nd. UBS Group set a $60.00 price target on Omnicell and gave the company a "buy" rating in a research report on Friday, March 13th. Bank of America upgraded Omnicell from a "neutral" rating to a "buy" rating and set a $70.00 price target on the stock in a report on Wednesday, February 4th. Finally, Zacks Research upgraded Omnicell from a "strong sell" rating to a "hold" rating in a report on Tuesday, March 10th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $59.00.

Insider Activity at Omnicell

In other news, EVP Corey J. Manley sold 7,405 shares of the stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $34.69, for a total value of $256,879.45. Following the completion of the sale, the executive vice president directly owned 96,717 shares of the company's stock, valued at $3,355,112.73. This represents a 7.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 2.52% of the stock is currently owned by company insiders.

Institutional Trading of Omnicell

Several institutional investors and hedge funds have recently modified their holdings of OMCL. Raymond James Financial Inc. purchased a new stake in shares of Omnicell in the second quarter worth approximately $26,000. Kemnay Advisory Services Inc. purchased a new stake in shares of Omnicell in the fourth quarter worth approximately $58,000. Parkside Financial Bank & Trust raised its stake in shares of Omnicell by 1,708.1% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,338 shares of the company's stock worth $61,000 after purchasing an additional 1,264 shares during the last quarter. Van ECK Associates Corp raised its stake in shares of Omnicell by 75.1% in the fourth quarter. Van ECK Associates Corp now owns 2,294 shares of the company's stock worth $104,000 after purchasing an additional 984 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in shares of Omnicell by 385.5% in the second quarter. Tower Research Capital LLC TRC now owns 4,952 shares of the company's stock worth $146,000 after purchasing an additional 3,932 shares during the last quarter. 97.70% of the stock is owned by hedge funds and other institutional investors.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company's offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell's analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.